Aperio Group LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 7.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,440,246 shares of the biopharmaceutical company’s stock after buying an additional 240,071 shares during the quarter. Pfizer makes up 0.7% of Aperio Group LLC’s holdings, making the stock its 16th biggest position. Aperio Group LLC owned about 0.06% of Pfizer worth $122,817,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after purchasing an additional 9,239,499 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after purchasing an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after purchasing an additional 2,028,313 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in Pfizer by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after purchasing an additional 1,085,437 shares during the last quarter. Finally, LSV Asset Management lifted its holdings in Pfizer by 0.6% during the 2nd quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock valued at $1,117,726,000 after purchasing an additional 199,100 shares during the last quarter. 69.74% of the stock is owned by institutional investors.
PFE has been the subject of several research reports. Jefferies Group set a $37.00 price target on Pfizer and gave the company a “neutral” rating in a report on Monday, September 18th. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Tuesday, October 3rd. Finally, ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $38.83.
Pfizer Inc. (NYSE:PFE) opened at $36.54 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a 12-month low of $30.90 and a 12-month high of $37.35. The company has a market capitalization of $217,800.00, a price-to-earnings ratio of 22.42, a P/E/G ratio of 2.44 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter last year, the business earned $0.61 earnings per share. Pfizer’s revenue was up .9% on a year-over-year basis. analysts expect that Pfizer Inc. will post 2.59 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be given a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.
Pfizer announced that its board has authorized a stock repurchase plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.
In related news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock worth $1,065,220 in the last 90 days. 0.06% of the stock is owned by company insiders.
WARNING: “Aperio Group LLC Purchases 240,071 Shares of Pfizer Inc. (PFE)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/14/aperio-group-llc-buys-240071-shares-of-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.